Bavarian Nordic could be first on the RSV market in China

A new partnership deal with Nuance Pharma turns Bavarian Nordic’s sights to China. CFO Henrik Juuel opens up about the chance for Bavarian Nordic to be first on the market – a very lucrative position for the firm.

Henrik Juuel, CFO at Bavarian Nordic | Photo: Bavarian Nordic PR

The race to the RSV market is fully underway, and on Monday, Bavarian Nordic began sprinting – at least in the direction of the Chinese market.

Bavarian Nordic announced that it had signed a license and commercialization deal with Shanghai-based biotech company Nuance Pharma for the Danish firm’s RSV vaccine candidate, MVA-BN RSV, for people over the age of 60.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs